Results 261 to 270 of about 1,140,223 (331)

Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-γ production of lymphocytes

, 1992
Shinichi Ikemoto, Seiji Wada, Masato Kamizuru, N Hayahara, Taketoshi Kishimoto, Masanobu Maekawa   +5 more
openalex   +1 more source

Multimodality Imaging Features of Papillary Renal Cell Carcinoma. [PDF]

Diagnostics (Basel)
Comune R, Tiralongo F, Bicci E, Saturnino PP, Ronza FM, Bortolotto C, Granata V, Masala S, Scaglione M, Sica G, Tamburro F, Tamburrini S.   +11 more
europepmc   +1 more source

A CASE OF ACQUIRED CYSTIC DISEASE OF BILATERAL KIDNEYS WITH RENAL CELL CARCINOMA FOLLOWING LONG-TERM HEMODIALYSIS

, 1991
Akinobu Gotoh, Kazuo Gohji, Yohei Mizuno, S Arakawa, O. Matsumoto, S Kamidono, Nozomu Yamanaka, Sanghoon Shin   +7 more
openalex   +2 more sources

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Belzutifan for the treatment of renal cell carcinoma. [PDF]

Ther Adv Med Oncol
Wu X, Lazris D, Wong R, Tykodi SS.
europepmc   +1 more source

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

Cancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai, Tao Fan, Chu Xiao, Ziqin Deng, Yixiao Liu, Chunxiang Li, Jie He   +6 more
wiley   +1 more source

Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC). [PDF]

Int J Mol Sci
Rysz J, Ławiński J, Franczyk B, Gluba-Sagr A.   +3 more
europepmc   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source